Healthcare
Roche Holding AG(RHHBF)
Live Price
Offline$410.00
+1.49% today
1Y Change
+25.93%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $253.45B
- Revenue Growth
- -1.4%
- EPS Growth
- +55.8%
- Dividend Yield
- 3.1%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Roche Holding AG (RHHBF) is a Healthcare stock with a market cap of $253.45B and listed on OTC. The stock last traded around $410.00 and up 25.9% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of -1.4%, EPS growth of +55.8%, a dividend yield of 3.1%. What stands out right now is revenue -1.4%, EPS +55.8%, free cash flow -6.6% with operating margin 28.9% and ROIC 18.8%. The dividend matters to the case here, with a current yield around 3.1%. Valuation sits in the middle of the pack at P/E 19.7 and price/sales 4.1. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines RHHBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-1.4% vs +7.6% peer median
Operating Margin
Above sector median
+28.9% vs +19.4% peer median
P/E
Below sector median
19.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Jan 29, 2026 with an EPS surprise of -2.5% and a revenue surprise of -1.7%.
The operating picture looks softer than before
Revenue is at -1.4% and EPS is at +55.8%, with operating margin around 28.9%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 23, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jan 29, 2026 | -2.5% | +0.0% | +8.0% | +12.8% |
2025 Jul 24, 2025 | -55.9% | -5.4% | -4.6% | -7.3% |
2025 Jan 30, 2025 | -70.0% | +2.0% | -0.0% | +1.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RHHBF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RHHBF Max Drawdown
-24.85%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RHHBF and SPY.
Company Overview
Roche Holding AG
Other OTC
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). The company was founded in 1896 and is headquartered in Basel, Switzerland.
- Leadership
- Thomas Schinecker
- IPO Date
- Aug 3, 2012
- Employees
- 103.2k
- Street Address
- Konzern Hauptsitz
- Mailing
- Basel, 4070
- Region
- Basel, CH
- Reporting Currency
- USD
- Investor Line
- 41 61 688 11 11
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 19.7
- EV/EBITDA
- 12.3
- Price/Sales
- 4.1
- Price/Book
- 7.5
Growth
- Revenue
- -1.4%
- EPS
- +55.8%
- Free Cash Flow
- -6.6%
Profitability
- Gross Margin
- 73.5%
- Operating Margin
- 28.9%
- Net Margin
- 20.9%
- ROE
- 41.2%
- ROIC
- 18.8%
Balance Sheet
- Debt/Equity
- 0.94
- Current Ratio
- 1.38
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.